JP6312226B2 - 透析装置、リポソーム製造装置、及びリポソーム製造方法 - Google Patents
透析装置、リポソーム製造装置、及びリポソーム製造方法 Download PDFInfo
- Publication number
- JP6312226B2 JP6312226B2 JP2016542546A JP2016542546A JP6312226B2 JP 6312226 B2 JP6312226 B2 JP 6312226B2 JP 2016542546 A JP2016542546 A JP 2016542546A JP 2016542546 A JP2016542546 A JP 2016542546A JP 6312226 B2 JP6312226 B2 JP 6312226B2
- Authority
- JP
- Japan
- Prior art keywords
- liposome
- liquid
- flow path
- hollow fiber
- flow rate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002502 liposome Substances 0.000 title claims description 239
- 238000000502 dialysis Methods 0.000 title claims description 180
- 238000004519 manufacturing process Methods 0.000 title claims description 72
- 239000007788 liquid Substances 0.000 claims description 214
- 239000012510 hollow fiber Substances 0.000 claims description 133
- 239000012528 membrane Substances 0.000 claims description 54
- 238000000746 purification Methods 0.000 claims description 28
- 239000002699 waste material Substances 0.000 claims description 24
- 238000011084 recovery Methods 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 description 91
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- 238000000034 method Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 18
- 239000002994 raw material Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 239000010419 fine particle Substances 0.000 description 13
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 12
- 108010036949 Cyclosporine Proteins 0.000 description 11
- 229960001265 ciclosporin Drugs 0.000 description 11
- 229930182912 cyclosporin Natural products 0.000 description 11
- 239000002612 dispersion medium Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 238000011144 upstream manufacturing Methods 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920002725 thermoplastic elastomer Polymers 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000010924 continuous production Methods 0.000 description 4
- 238000009413 insulation Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000004014 plasticizer Substances 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000004695 Polyether sulfone Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229920006393 polyether sulfone Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 229920001187 thermosetting polymer Polymers 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 229920001973 fluoroelastomer Polymers 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000005401 electroluminescence Methods 0.000 description 1
- BXOUVIIITJXIKB-UHFFFAOYSA-N ethene;styrene Chemical group C=C.C=CC1=CC=CC=C1 BXOUVIIITJXIKB-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/32—Controlling or regulating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/243—Dialysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/24—Dialysis ; Membrane extraction
- B01D61/28—Apparatus therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/02—Hollow fibre modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/16—Flow or flux control
- B01D2311/165—Cross-flow velocity control
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2649—Filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/24—Specific pressurizing or depressurizing means
- B01D2313/243—Pumps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/50—Specific extra tanks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/10—Cross-flow filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/22—Membrane contactor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Water Supply & Treatment (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
Description
以下、主に図9及び図10を参照して、図1に示されるリポソーム製造装置10を実際に用いて被透析液の濃度を制御した実験(実施例1)について説明する。
まず、実験に用いた装置について説明する。
次に、実験に用いた被透析液及び外液21aについて説明する。
実験では、リポソーム連続製造装置(Lipo−TB)により製造したリポソーム液11bを、中空糸透析カラム20を用いて透析した。製造と透析とを連続して行った。透析では、各リポソーム液11bに、第1流路201の入口20aから出口20bまでを1回だけ通過させた。この際、第1流路201の入口20aにおける被透析液の流速(カラム入口の流速)を一定(2.00mL/分)に保ち、第1流路201の出口20bにおける被透析液の流速(カラム出口の流速)を変化させた。詳しくは、ポンプ16aの流速の設定値を変えることによってカラム出口の流速を変化させた。図9に、実験条件(条件1−1〜1−3)及び実験結果(リポソーム液11bの濃度)を示す。
以下、主に図11を参照して、図1に示されるリポソーム製造装置10を実際に用いて被透析液の濃度を制御した実験(実施例2)について説明する。なお、実施例2の条件は、以下の点以外は、実施例1の条件と同様である。
以下、主に図12(a)及び図12(b)を参照して、図1に示されるリポソーム製造装置10を実際に用いて被透析液の濃度を制御した実験(実施例3)について説明する。なお、実施例3の条件は、以下の点以外は、実施例1の条件と同様である。
以下、主に図13(a)及び図13(b)を参照して、図1に示されるリポソーム製造装置10を実際に用いて被透析液の濃度を制御した実験(実施例4)について説明する。なお、実施例4の条件は、以下の点以外は、実施例1の条件と同様である。
第1流路201の入口20aにおける被透析液の流速を3mL/分〜4mL/分にして、4本の中空糸透析カラム(MidiKrosモジュール)を長手方向に(直列に)つなげることで、約4Lの量の被透析液(リポソーム液)を約20時間かけて処理(透析及び濃縮)することができた。
10a 原料供給部
10b 透析液供給部
11 容器
11a 原料
11b リポソーム液
12 管
12a ポンプ
13 製造部
14 管
15 精製部
16 管
16a ポンプ
16b 流路面積可変装置
17 回収部
20 中空糸透析カラム
20a 入口
20b 出口
20c 入口
20d 出口
21 容器
21a 外液
22 管
22a ポンプ
23 管
24 廃液容器
30 制御ユニット
31 制御部
32 検出部
41 入力部
42 表示部
43 記憶部
44 インターフェイス
101 リポソーム
101a 脂質分子
101b 親水部
101c 疎水部
101d 修飾剤
101e 薬剤
102 分散媒
103 有機微粒子
131〜133 槽
131b〜133b 温度センサ
131a〜133a 恒温槽
134 滅菌フィルタ
201 第1流路
201a 中空糸膜
201b 孔
202 第2流路
Claims (7)
- 中空糸膜と、前記中空糸膜の内側に被透析液を流すための第1流路と、前記中空糸膜の外側に外液を流すための第2流路とを有する中空糸透析カラムと、
前記第1流路の入口に前記被透析液を送る送液部と、
前記第1流路の出口から流出する時の前記被透析液の流速を変更可能とする流速可変部と、
を備え、
前記流速可変部は、前記第1流路の出口よりも下流側に設けられ、前記第1流路の出口から流出した前記被透析液を所定の流速で下流に送るポンプから構成される、透析装置。 - 前記第2流路内の前記外液が、前記第1流路内の前記被透析液の流れに対向する向きに流れる、請求項1に記載の透析装置。
- 中空糸膜と、前記中空糸膜の内側に被透析液を流すための第1流路と、前記中空糸膜の外側に外液を流すための第2流路とを有する中空糸透析カラムと、
前記第1流路の入口に前記被透析液を送る送液部と、
前記第1流路の出口から流出する時の前記被透析液の流速を変更可能とする流速可変部と、
を備え、
前記第2流路の出口には管を介して廃液容器が接続されており、
前記廃液容器は、前記中空糸透析カラムよりも低い位置に配置されており、
前記第2流路の出口にフィルタが設けられている、透析装置。 - リポソームを含むリポソーム液を製造する製造部と、
前記製造されたリポソーム液を精製する精製部と、
前記精製されたリポソーム液を回収する回収部と、
を備え、
前記製造部と前記精製部と前記回収部とは、互いに密閉可能に連結されており、
前記精製部は、
中空糸膜と、前記中空糸膜の内側にリポソーム液を流すための第1流路と、前記中空糸膜の外側に外液を流すための第2流路とを有する中空糸透析カラムと、
前記第1流路の出口から流出する時の前記リポソーム液の流速を変更可能とする流速可変部と、
を備え、
前記流速可変部は、前記第1流路の出口よりも下流側に設けられ、前記第1流路の出口から流出した前記リポソーム液を所定の流速で下流に送るポンプから構成される、リポソーム製造装置。 - 前記リポソーム液は、前記第1流路の入口から出口までを1回だけ通過する、請求項4に記載のリポソーム製造装置。
- リポソームを含むリポソーム液を製造することと、
前記製造されたリポソーム液を、請求項1に記載の透析装置により透析することと、
を含む、リポソーム製造方法。 - リポソームを含むリポソーム液を製造することと、
前記製造されたリポソーム液を、請求項3に記載の透析装置により透析することと、
を含む、リポソーム製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014163828 | 2014-08-11 | ||
JP2014163828 | 2014-08-11 | ||
PCT/JP2015/072287 WO2016024510A1 (ja) | 2014-08-11 | 2015-08-05 | 透析装置、リポソーム製造装置、被透析液の濃度制御装置、及び被透析液の濃度制御方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016024510A1 JPWO2016024510A1 (ja) | 2017-07-13 |
JP6312226B2 true JP6312226B2 (ja) | 2018-04-18 |
Family
ID=55304139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016542546A Active JP6312226B2 (ja) | 2014-08-11 | 2015-08-05 | 透析装置、リポソーム製造装置、及びリポソーム製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11633699B2 (ja) |
JP (1) | JP6312226B2 (ja) |
WO (1) | WO2016024510A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6968452B2 (ja) * | 2017-11-01 | 2021-11-17 | 国立大学法人大阪大学 | 所望の粒径を有する脂質粒子を製造するための方法および装置の開発 |
US10792594B2 (en) * | 2017-12-28 | 2020-10-06 | Replegin Corporation | Dual pumping arrangement for a hollow fiber filter |
US11241656B2 (en) | 2018-11-29 | 2022-02-08 | Watersep Bioseparations Llc | Single pass cross flow diafiltration module and method |
US11524262B2 (en) * | 2019-08-05 | 2022-12-13 | Repligen Corporation | Devices, systems, and methods for continuous processing with alternating tangential flow |
CN116528839A (zh) | 2020-12-04 | 2023-08-01 | 瑞格国际生技股份有限公司 | 药代动力学被改善的含CD1d配体化合物的脂质体制剂 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5488882A (en) | 1977-12-26 | 1979-07-14 | Agency Of Ind Science & Technol | Solute separating method by dialysis |
ATE77051T1 (de) | 1988-03-04 | 1992-06-15 | Takeda Chemical Industries Ltd | Liposom-zusammensetzung. |
JP2916684B2 (ja) * | 1988-03-04 | 1999-07-05 | 武田薬品工業株式会社 | リポソーム製剤の精製法 |
US5057226A (en) * | 1988-05-18 | 1991-10-15 | Cobe Laboratories, Inc. | Treatment of liquid including blood components |
JPH05155758A (ja) | 1991-12-11 | 1993-06-22 | Nippon Oil & Fats Co Ltd | ヘモグロビン内包脂質小胞体の製造方法 |
JP2961481B2 (ja) | 1993-08-30 | 1999-10-12 | サイテック株式会社 | 血液透析器兼血液濾過器 |
JPH08295697A (ja) * | 1995-04-26 | 1996-11-12 | Kanebo Ltd | 高濃度絹フィブロイン水溶液の製造方法 |
WO1999025319A1 (en) * | 1997-11-14 | 1999-05-27 | Depotech Corporation | Production of multivesicular liposomes |
JP4158333B2 (ja) * | 2000-12-01 | 2008-10-01 | ニプロ株式会社 | 血液浄化装置 |
JP4173969B2 (ja) | 2002-03-14 | 2008-10-29 | 旭化成クラレメディカル株式会社 | 血液透析ろ過器及び血液透析ろ過装置 |
JP4617458B2 (ja) | 2004-02-10 | 2011-01-26 | 財団法人ヒューマンサイエンス振興財団 | 中空糸透析カラムを利用したリポソームの製造方法 |
JP4868772B2 (ja) * | 2004-08-24 | 2012-02-01 | 日機装株式会社 | 血液浄化装置 |
US20080035568A1 (en) * | 2005-10-03 | 2008-02-14 | Zhongping Huang | Apparatus and Method for Filtering Fluids |
JP2007268257A (ja) * | 2006-03-10 | 2007-10-18 | Asahi Kasei Medical Co Ltd | 血液透析装置 |
WO2009073567A1 (en) * | 2007-11-29 | 2009-06-11 | Xcorporeal. Inc. | System and method for conducting hemodialysis and hemofiltration |
KR20090118536A (ko) * | 2008-05-14 | 2009-11-18 | 탑엠앤에이 주식회사 | 혈액 투석장치 |
JP5771366B2 (ja) * | 2009-09-02 | 2015-08-26 | 株式会社バイオメッドコア | リポソーム製造装置及び方法 |
-
2015
- 2015-08-05 JP JP2016542546A patent/JP6312226B2/ja active Active
- 2015-08-05 US US15/502,736 patent/US11633699B2/en active Active
- 2015-08-05 WO PCT/JP2015/072287 patent/WO2016024510A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
JPWO2016024510A1 (ja) | 2017-07-13 |
US20170232390A1 (en) | 2017-08-17 |
WO2016024510A1 (ja) | 2016-02-18 |
US11633699B2 (en) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6312226B2 (ja) | 透析装置、リポソーム製造装置、及びリポソーム製造方法 | |
AU2018202721B2 (en) | Fluid circuit for delivery of renal replacement therapies | |
Forster et al. | Liposome-supported peritoneal dialysis for detoxification of drugs and endogenous metabolites | |
US20180353668A1 (en) | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection | |
AU2014212130B2 (en) | Degassing module for a controlled compliant flow path | |
US9526822B2 (en) | Sodium and buffer source cartridges for use in a modular controlled compliant flow path | |
US20220160947A1 (en) | Methods of Amelioration of Cerebrospinal Fluid and Devices and Systems Therefor | |
CN105008893A (zh) | 用于血液透析系统的pH缓冲剂测量系统 | |
ES2821698T3 (es) | Dispositivo de hemoperfusión portable | |
EP2957306A1 (en) | Blood purification column | |
AU2014212136A1 (en) | Systems and methods for multifunctional volumeteric fluid control | |
Pradhan et al. | A facile microfluidic method for production of liposomes | |
CN104583386A (zh) | 浓缩穿过细胞生长腔室循环的流体的组分 | |
CN106999640A (zh) | 体腔液处理系统 | |
Bhattacharjee et al. | Electrohydrodynamic transport of non‐symmetric electrolyte through porous wall of a microtube | |
Narendran et al. | Experimental Demonstration of Compact Polymer Mass Transfer Device Manufactured by Additive Manufacturing with Hydrogel Integration to Bio-Mimic the Liver Functions | |
Gulyakin et al. | Use of Membrane Filters in Production Technology for Sterile Drugs | |
EP3903851A1 (en) | Peritoneal dialysis fluid from concentrate containers | |
US20220355015A1 (en) | Csf diagnostics platform | |
US20220096745A1 (en) | Subarachnoid fluid conduit system and kit | |
CA3226884A1 (en) | Csf diagnostics platform | |
JP2011140468A (ja) | 薬剤内包リポソームの製造方法及び薬剤内包リポソームの製造装置 | |
Sharma | Water-in Water (W/W) Emulsion Drug Delivery Systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170206 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180315 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6312226 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |